Latest Content

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

Reductions in antibody function, not IgG titers, distinguishes efgartigimod responders in myasthenia gravis.

HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes unproven.

At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.

Frailty, but not HIV serostatus, is tied to more severe lower urinary tract symptoms in adults with and at risk for HIV, a cross-sectional study finds.